Table 1 Patient and Transplant Characteristics.

From: Sequential quantification of T-cell receptor excision circles (TRECs) and K-deleting recombination excision circles (KRECs) and overall survival after allogeneic HSCT

Characteristics (374 alloHSCT in 350 patients)

Recipient age

45 (16–68)

Recipient sex (male)

223 (59.6%)

Disease

- AL/MDS

261 (69.8%)

- CLPD

83 (22.2%)

- Myeloma

30 (8%)

Donor type

- Matched related

198 (52.9%)

- Matched unrelated

49 (13.1%)

- Unrelated cord blood

114 (30.5%)

- Haploidentical

13 (3.5%)

Stem cell source

- Peripheral blood

258 (68.9%)

- Bone marrow

2 (0.5%)

- Umbilical cord blood

114 (30.5%)

Conditioning (MAC)

191 (51%)

GVHD prophylaxis

- CNI + MTX

198 (52.9%)

- CNI + MTX + ATG

49 (13.3%)

- CNI + MP + ATG

114 (30.5%)

- PTCy

13 (3.5%)

AlloHSCT Number

- First

350 (93.6%)

- Second

21 (5.6%)

- Third

3 (0.8%)

  1. AlloHSCT Allogeneic haematopoietic stem cell transplantation, AL/MDS Acute Leukaemia/myelodysplastic Syndrome, ATG thymoglobulin, CLPD chronic lymphoproliferative disorder, CNI calcineurin inhibitor, GVHD graft versus host disease, MAC myeloablative conditioning, MP methylprednisolone, MTX methotrexate, PTCy post-transplant cyclophosphamide.
  2. Age is presented as median (range), and all other variables are presented as number of cases (percentage).